Kombinirovannaya terapiya bolevoy diabeticheskoy polineyropatii: rezul'taty pilotnogo issledovaniya


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Neuropathic pain as a manifestation of diabetic polyneuropathy (DPN) is a leading cause of seeking medical care for patients with diabetes mellitus. Limited efficacy of existing therapies is the main problem in the management of these patients. The main objective of the study was to assess the efficacy and safety of symptomatic, pathogenetic and combination therapy in patients with chronic painful DPN with moderate and severe sensory deficit, who were nonresponders to intravenous treatment with α-lipoic acid (ALA). Additional aim was to evaluate the efficacy and safety of combination therapy with gabapentin and gabapentin + vitamin B complex (Kombilipen® Tabs) in patients resistant to monotherapy with gabapentine. Prolonged use of ALA, as well as additional treatment with B vitamins in patients with moderate to severe painful DPN, which are nonresponders to intravenous therapy with ALA, had a small effect. In this situation, the appointment of symptomatic drugs with central action (gabapentin) as both monotherapy and in combination with ALA is reasonable. Application of a complex of B vitamins (Kombilipen® tabs) in patients-nonresponders to gabapentin is accompanied by an additional significant reduction in the severity of neuropathic pain.

Texto integral

Acesso é fechado

Bibliografia

  1. Abbott C.A., Malik R.A., et al. Prevalence and Characteristics of Painful Diabetic Neuropathy in a Large Community-Based Diabetic Population in the U.K. Diabetes Care. 2011; 34: 2220-204.
  2. Cabezas-Cerrato J. The prevalence of diabetic neuropathy in Spain: a study in primary care and hospital clinic groups. Diabetologia. 1998; 41: 1263-69.
  3. Chaparro L.E., Wiffen P.J., Moore R.A., Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Library. 2012; Issue 7. doi: 10.1002/14651858.CD008943.pub2
  4. Davies M., Brophy S., Williams R., Taylor A. The Prevalence, Severity, and Impact of Painful Diabetic Peripheral Neuropathy in Type 2 Diabetes. Diabetes Care. 2006; 29: 1518-22.
  5. DCCT (The Diabetes Control and Complications Trial Research Group). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993; 329: 977-86.
  6. Dyck P.J., Katz K.M., Karnes J.L., Litchy W.J., et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993; 43: 817-24.
  7. Fisher T.Z., Waxman S.G. Neuropathic pain in diabetes-evidence fore a central mechanism. Nature. Rev. Neurol. 2010; 462-66.
  8. Fraser D.A., Diep L.M., Hovden I.A., et al. Diabetes Care. 2012; 35(5): 1095-97.
  9. Hartemann A., Attal N., Bouhassira D., et al. Painful diabetic neuropathy: diagnosis and management. Diabetes Metab. 2011; 37(5): 377-88.
  10. Haupt E., Ledermann H., Köpcke W. Benfotiamine in the treatment of diabetic polyneuropathy-a three-week randomized, controlled pilot study (BEDIP study). Int. J. Clin. Pharmacol. Ther. 2005; 43(2): 71-7.
  11. Jacobs A.M., Cheng D. Addition of Metanx in pregabalin partial responders for painful diabetic neuropathy. Journal of Diabetes Mellitus 2013; 3(3): 134-38.
  12. Kumar S., Ashe H.C., Parnell L.N., et al. The prevalence of foot ulceration and its correlates in type 2 diabetes: a population-based study. Diabet. Med. 1994; 11: 480-84.
  13. Man-chun Wong and Joanne W.Y. Chung. Chapter 14 in Erin Lawson, Miroslav Backonja. Painful Diabetic Polyneuropathy. A Comprehensive Guide for Clinicians. doi: 10.1007/978-1-4614-6299-6. Springer New York Heidelberg Dordrecht London. 2013.
  14. Medina-Santillan R., Morales-Franco G., Espinoza-Raya J., et al. Treatment of Diabetic Neuropathic Pain with Gabapentin Alone or Combined with Vitamin B Complex. Preliminary Results. Proc. West. Pharmacol. Soc. 2004; 47: 109-12.
  15. Mixcoatl-Zecuatl T., Quinonez-Bastidas G.N., Caram-Salas N.L., et al. Synergistic antiallodynic interaction between gabapentin or carbamazepine and either benfotiamine or cyanocobalamin in neuropathic rats. Methods Find Exp. Clin. Pharmacol. 2008; 30(6): 431-41.
  16. Moore R., Wiffen P.J., Derry S., et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. The Cochrane Library. Published Online: 27 APR 2014. doi: 10.1002/14651858. CD007938.pub3.
  17. Pfiefer M.A., Schumer M.P. Clinical trials of diabetic neuropathy: Past, present and future. Diabetes. 1995; 44: 1355-61.
  18. Reyes-Garcia G., Caram-Salas N.L., Medina-Santillan R., Granados-Soto V. Oral administration of B vitamins increases the antiallodynic effect of gabapentin in the rat. Proc West Pharmacol Soc. 2004; 47: 76-9.
  19. Ruessmann H.-J. Switching from pathogenetic treatment with α-lipoic acid to gabapentin and other analgesics in painful diabetic neuropathy: a real-world study in outpatients. Journal of Diabetes and Its Complications. 2009; 4: 174-77.
  20. Sorensen L., Molyneaux L., Yue D.K. Insensate versus painful diabetic neuropathy: the effects of height, gender, ethnicity and glycaemic control. Diabetes Res. Clin. Pract. 2002; 57: 45-51.
  21. Stracke H., Gaus W., Achenbach U., et al. Benfotiamine in Diabetic Polyneuropathy (BENDIP): Results of a Randomised, Double Blind, Placebo-controlled Clinical Study. Exp. Clin. Endocrinol. Diabetes 2008; 116(10): 600-05.
  22. Young M.J., Boulton A.J.M., MacLeod A.F., et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993; 36: 150-54.
  23. Ziegler D., Gries F.A., Spuler M., Lessmann F. The epidemiology of diabetic neuropathy: DiaCAN Multicenter Study Group. Diabet. Med. 1993; 10(Suppl. 2): 82S-6S.
  24. Ziegler D. Painful Diabetic Neuropathy. Advantage of novel drugs over old drugs? Diabetes. 2009; 32(Suppl. 2): S414-19.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2014

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies